Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, July 28, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Hims & Hers Health, Inc. ("Hims & Hers Health" or the "Company") (NYSE: HIMS) investors of a class action representing investors that bought securities between April 29, 2025 and June 23, 2025, inclusive (the "Class Period"). Hims & Hers Health investors have until August 25, 2025 to file a lead plaintiff motion. Investors are encouraged to con ...

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action. Investors have until August 25, 2025, to ask th ...

SAN DIEGO, July 28, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, all dates inclusive (the "Class Period"), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers as well as certa ...

NEW YORK, July 26, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action. Investors have until August 25, 2025, to ask th ...

零售投资者兴趣激增 - 公司股票因高卖空比例和社交媒体关注度成为潜在“迷因股”热门候选 [1] - 过去一个月社交媒体讨论量激增近1000% 成为WallStreetBets论坛第12大热门提及股票 [3] - 周五收盘股价上涨0.79%至57.7美元 [8] 卖空压力与轧空潜力 - 公开流通股中33.5%（超6500万股）被卖空 远高于平均水平 [2] - 异常高的卖空比例使其成为零售交易者通过社交媒体协调轧空的理想目标 [2] 基本面与增长潜力 - 分析师预测下一年度每股收益(EPS)将增长178% [5] - 年度营收同比增长111% 用户规模扩张至240万订阅用户 [6] - 零售投资者关注其营销策略 产品创新和增长潜力作为看涨信号 [4] 行业关注度与机构评价 - 交易行为分析师指出零售投资者对创新趋势和品牌建设的敏感度是推动因素 [4] - 分析师认为只要持续保持增长创新和用户体验 零售投资者的参与热情将延续 [7] 潜在风险因素 - 与诺和诺德合作终止及集体诉讼案件引发部分投资者谨慎态度 [6]

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS). Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=157789&from=3 CLASS PERIOD: A ...

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action. Investors have until August 25, 2025, to ask th ...

This is where they were trading premarket at 7 a.m. ET Thursday. 1. Tesla The move: Elon Musk's EV maker is down about 6% to $313.44 a share after rising slightly over 0.1% on Wednesday. Why: Tesla reported disappointing second-quarter results before the closing bell on Wednesday, with revenue dropping 12% year-on-year — the biggest fall in a decade. Shares rose after the past two earnings reports, despite also being weak. Tesla's, Alphabet's, and IBM's second-quarter earnings are on investors' minds this m ...

SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers as well as certain of ...

诉讼背景 - 领先证券律师事务所Bleichmar Fonti & Auld LLP宣布对Hims & Hers Health Inc及其部分高管提起集体诉讼 指控其涉嫌违反联邦证券法 [1] - 诉讼依据为《1934年证券交易法》第10(b)和20(a)条款 案件由美国加州北区地方法院受理 案件编号分别为25-cv-05315和25-cv-05321 [2] 争议焦点 - 公司2025年4月29日与诺和诺德达成"长期合作" 立即在其平台销售减肥药Wegovy 主要成分为semaglutide [3] - 被指控向投资者虚假陈述合作性质 声称协议允许同时销售Wegovy和复合semaglutide 并误导其复合药物符合FDA规定 [4] 事件影响 - 诺和诺德2025年6月23日终止合作 指控公司违规销售仿制版Wegovy且危害患者安全 违反复合药物批量销售禁令 [5] - 消息公布后公司股价单日暴跌34% 从64.22美元/股跌至41.98美元/股 市值蒸发22.24美元/股 [5] 公司业务 - 运营远程医疗平台 提供在线医疗咨询 处方药和健康产品 合作涉及诺和诺德明星减肥药Wegovy的渠道销售 [3] 律所背景 - 代理律所曾为特斯拉董事会案件追回9亿美元 在Teva制药案中追偿4.2亿美元 [8]